GlassScriptPhysician profile
Sara E Hari
NPI 1265490833
$4,600.29
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,115 · 2022: $1,980 · 2023: $487 · 2024: $18.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $505.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,228.06 | 2021-2023 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $564.14 | 2021-2023 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $477.86 | 2021-2023 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Biohaven Pharmaceutical Holding Company LTD. | $282.06 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $240.31 | 2021-2023 | Farxiga |
| Abbvie INC. | $240.07 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $215.57 | 2021-2022 | |
| Amgen INC. | $187.46 | 2021-2022 | |
| Pfizer INC. | $186.25 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $185.98 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $148.08 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $125.01 | 2021 | |
| Astellas Pharma US INC | $116.02 | 2021-2022 | |
| Lilly USA, LLC | $42.59 | 2021 | |
| Jazz Pharmaceuticals INC. | $38.58 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $34.95 | 2021-2022 | |
| Eisai INC. | $31.98 | 2021 | |
| Dexcom, INC. | $29.52 | 2021 | |
| Currax Pharmaceuticals LLC | $29.06 | 2021 | |
| Upsher-Smith Laboratories LLC | $23.03 | 2023 | |
| Ibsa Pharma INC. | $21.47 | 2021 | |
| Bausch Health US, LLC | $17.91 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $16.95 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.59 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.52 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.20 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $15.13 | 2023 | |
| Endo Pharmaceuticals INC. | $14.34 | 2021 | |
| Lifescan, INC. | $14.01 | 2022 | |
| Merck Sharp & Dohme LLC | $12.82 | 2021 | |
| Smith+Nephew, INC. | $12.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Hari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.